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errors, but is a need of incorporating a more accurate 
algorithm for patients in which low density regions are 
involved. In fact we note a discrepancy between measured 
and planned dose in thoracic cases. It is due to the DC Pencil 
beam algorithm of dose reconstruction, that over-estimates 
dose in heterogeneous area. 
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In the framework of multimodality approaches combined 
radiochemotherapy for selected patients with bladder cancer 
already is accepted as alternative to radical cystectomy. 
Overall survival rates after five and ten years are 
comparable. The multimodality bladder preservation 
approach will be successful only in institutions with a close 
cooperation between urooncological and radiooncological 
partners. Combined radiochemotherapy is superior to 
radiation alone and therefore in a curative setting the use of 
simultaneous chemotherapy is mandatory. Further 
developments, e.g. brachytherapy, additional regional 
hyperthermia, the optimization of simultaneous 
chemotherapy, and the use of predictive biomarkers may 
further increase the results after organ-preserving 
multimodality treatment for patients with bladder cancer.  
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The therapeutic window of radiotherapy could be improved if 
tumor cells could be selectively rendered more sensitive to 
radiation. Such a strategy depends upon exploiting tumor 
specific targets, some of which, such as hypoxia in the 
microenvironment are well known, but many of which remain 
to be identified. The colony forming assay (CFA) is the ‘gold 
standard’ method for assessing intrinsic radiosensitivity in 
vitro. We have developed a technique to perform high-
throughput CFAs in 96 well plates and have recently 
completed siRNA screens of a selected DNA repair library and 
of approximately 10,000 additional genes, of which the 793 
gene ‘kinase’ section of the library has been examined in 
detail. The screens used a ranked-product analysis to identify 
the top hits. On the basis of the top candidate genes 
identified by the primary screen, a secondary library was 
then screened on multiple occasions. This work identified 
several genes such as ATM, ATR, DNA-PK and CHEK1, which 
are well known to play key roles in tumor cell 
radiosensitivity. In addition, we identified several novel 
genes whose depletion induced HeLa radiosensitisation in 6-
well plate CFAs. These experiments were repeated with 
separate siRNAs to ensure these findings were not the result 
of off-target effects. Depletion of these genes appeared to 
cause radiosensitisation in several other tumor cell lines as 
well. We are currently investigating the effects of several of 
these genes in greater detail. Ongoing work will be presented 
that clarifies the effects of gene knockdown on radio- in 
several tumor and normal tissue lines. The mechanism by 
which this knockdown causes these effects will also be 
presented for some of the targets. Tumor hypoxia is probably 
the major determinant of clinical outcome other than 
intrinsic radiosensitivity. Most work so far has concentrated 
on vascular effects in oxygen delivery as a determinant of 
this, but in fact oxygen consumption by the tumor cells is 
also a determinant of tumor oxygen concentration. We have 
developed screens for oxygen consumption. We used both the 
Pharmakon 1600 and Oncology drug set libraries for the 
screening. Our primary screen identified 100 compounds that 
reduced oxygen consumption (OCR) without significantly 
affecting cell death in FaDu hypopharyngeal cells. A 
secondary screen identified 50 compounds that reduced 
oxygen consumption (OCR) without significantly affecting cell 
death in either FaDu hypopharyngeal cells or MRC5 lung 
fibroblasts. The results of these “microenvironmental” 
screens will also be discussed.  
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The availability of Monte Carlo (MC)-based codes optimized 
for photon and electron beams in patient-specific geometries 
has lead to the development of several different MC-based 
dose calculation systems for radiotherapy treatment 
planning. MC-based photon beam dose calculations today are 
performed within minutes in the routine clinical setting.  As 
MC-based planning systems become more widely utilized in 
the clinic, it is critical that paradigms and approaches for 
clinical commissioning and implementation of these systems 
be formulated and discussed.  This lecture will focus on such 
strategies in the context of MC calculations for external 
photon and electron beam radiotherapy.  The following 
topics will be covered: (a) Overview of the MC method for 
radiotherapy photon beam simulation; (b) Review of the 
methods used for characterization of the linear accelerator 
(linac) and patient simulation; (c) Techniques for 
commissioning and experimental verification of MC-based 
dose calculation systems, and associated challenges; (d) 
Tools for facilitating MC-based treatment planning in the 
clinical setting, e.g. methods for viewing of isodose plans 
with their combined statistical uncertainty distributions; (e) 
Issues specific to MC-based electron beam dose calculations.  
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Finally, as with any emerging technology it is important that 
we understand its clinical ramifications: How is the use of the 
MC method likely to impact patient outcomes? Methods 
toward clearly addressing this question are fraught with 
challenges. We will summarize the approaches being used in 
evaluating the clinical impact of MC-based photon dose 
calculations and will discuss the associated issues.  
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In 1916 Dr. C. Thurston Holland addressed the role of the 
professionals that we now know as RTTs in the following 
terms:  “The place of these people…..is merely that of 
assistants.  They work directly under medical control, accept 
no responsibilities of any kind, and merely do as they are 
told” 
Radiotherapy practice is unrecognizable in 2015 when 
compared to the time when this statement was made.  
 Almost a century later RTTs have largely become recognized 
as professionals who contribute significantly to the activities 
carried out in our radiotherapy departments.   However 
achieving professional recognition has been a long and 
contentious road that despite gathering momentum in recent 
decades and has a long way to go.    
Being a part of the radiotherapy team in the current 
environment is stimulating, exciting and rewarding and the 
opportunities post 2020 are immense.  In this rapidly 
changing environment professional practice must be 
constantly adapted to keep, not only abreast, but ahead of 
the scientific and technological developments.   RTTs must 
review and reconsider the way they practice and be prepared 
to move from the traditional to the innovative.  RTTs are 
rapidly becoming the drivers of their own practice, have met 
the challenges and adapted readily to the spectrum of 
technology now in routine use and must continue to do so.     
What does the future hold?  Adaptive planning will be 
routine, biological treatment planning will be coming into 
practice, new molecular approaches will be coming on 
stream all leading to individualized treatment for patients.  
Choice of treatment plan based on image evaluation will be 
normal practice for the RTT and will bring about a changing 
relationship with their patient and other members of the 
team.   For RTTs the challenges of 2020 are immense and we 
must also position ourselves to be ready to meet these 
challenges and provide care to our patients consistent with 
the ESTRO Vision Statement: “challenges of individualised 
patient care will be achieved by integrating new clinical and 
preclinical evidence from biology, molecular/functional 
imaging and the use of new systemic agents together with 
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At present, standard RT volume is the whole prostate gland, 
as is the case of radical prostatectomy. This is due to 2 
factors: 1) multifocal intraprostatic spread of prostate cancer 
and 2) impossibility to identify tumor foci on the standard RT 
planning imaging modality (computer tomography, [CT]). 
However, the whole organ one-dose level RT is rarely used in 
solid tumors. Localized approach, i.e. RT to tumor site only 
or to the whole organ followed by boost to tumor site is 
common. Several reports have demonstrated that 
 dominant/biggest intraprostatic lesion (DIL) is the major site 
of recurrence after prostate cancer RT. Introduction of new 
imaging technologies (Positron Emission Tomography [PET], 
Single PET [SPECT], extended transrectal ultrasound [TRUS]-
biopsies, Doppler ultrasound and multiparametric magnetic 
resonance [mpMRI]) has allowed to identify DIL. According to 
the international consensus, mpMRI including T2-weighted 
imaging (T2WI), diffusion weighted imaging (DWI) and 
dynamic contrast enhanced (DCE) images represents the 
optimal current prostate imaging1. This opens 2 new 
scenarios: 1) boosting DIL concomitantly/sequentially to the 
whole prostate RT and 2) partial prostate irradiation (PPI) 
i.e. primary focal RT. 
As far as DIL boosting is concerned, up till now 11 series (833 
pts) have been published2. Both external beam RT (EBRT) and 
brachytherapy (BRT) have been used as boost, with 8 Gy (3-
35Gy) or 150% (130-155%) boost/whole prostate dose, 
respectively. DIL boost has been studied mainly in the 
conventional fractionation (IMRT + simultaneous integrated 
boost [SIB]), and only recently DIL SIB for extreme 
hypofractionation has been evaluated. 5 planning studies (3 
 EBRT and 2 BRT, 65 pts) have been published, comparing 
different RT techniques (see fig. as example) and different 
dose schemes (128% mean ratio boost/whole prostate dose, 
range 110-150%). 2 studies on patient series have been 
published (76 pts) using EBRT or high-dose-rate (HDR) BRT 
(112% mean ratio between boost/whole prostate dose, range 
108-116%). Delivering DIL SIB in extreme hypofractionation 
appears feasible but should be approached with caution. 
Clinical value of DIL dose escalation is unknown. Ongoing 
trials like FLAME, HEIGHT, DELINEATE, NCT01409473 and 
NCT01913717 will contribute to further assessment of 
boosting DIL. 
Primary focal therapy has been explored for 20 years now 
and more than 2000 patients have been treated3 (mainly with 
cryosurgery, high-intensity ultrasound [HIFU], photodynamic 
